#Canada #Edmonton #Nanostics Inc #ClarityDX Prostate #CPSA Accreditation

Nanostics Receives CPSA Accreditation for New Clinical Laboratory

Nanostics Inc., a pioneering company in precision health, has announced a significant achievement in the field of medical diagnostics. The firm recently received provisional accreditation from the College of Physicians and Surgeons of Alberta (CPSA) for its newly relocated clinical laboratory. This state-of-the-art facility is situated within the Biotechnology Business Development Centre (BBDC) at Edmonton Research Park, which is managed by Applied Pharmaceutical Innovation (API).

The move signifies a new chapter for Nanostics, previously operating from the Alberta Precision Laboratories’ facilities in downtown Edmonton. With this transition, the company is not just changing locations; it is also expanding its capabilities and readiness to enhance its service offerings. The new lab is larger and equipped to facilitate further growth and innovation, aligning perfectly with the company's mission to improve the clinical outcomes for men facing prostate cancer.

John Lewis, the CEO of Nanostics, expressed enthusiasm for this new phase, noting, “Relocating our clinical testing lab to BBDC is a major milestone for Nanostics. This new facility offers us expanded laboratory space, providing greater capacity for growth as we continue fulfilling our goal to improve clinical outcomes for men facing prostate cancer.” The company, through its ClarityDX® technology, offers diagnostic solutions, including the ClarityDX Prostate test, which identifies men at risk of aggressive prostate cancer.

This accreditation allows Nanostics to proceed confidently with its ClarityDX Prostate test in Canada. This particular test is crucial given that approximately 1 in 8 men in North America will be diagnosed with prostate cancer; alarmingly, 1 in 44 will succumb to the disease, making it one of the leading causes of cancer-related deaths in men. The role of ClarityDX Prostate in this scenario cannot be overstated, as it aids in distinguishing between low-risk and aggressive forms of prostate cancer.

The ClarityDX Prostate test employs a combination of biological data, clinical information, and artificial intelligence to calculate a risk score for aggressive prostate cancer. This approach represents a substantial advancement in decision-making for healthcare providers and patients alike, particularly when interpreting results from high PSA levels or concerning Digital Rectal Exam (DRE) findings.

The dedication to innovation seen at Nanostics is mirrored in the environment fostered by the BBDC. This facility is intended to support high-potential life sciences companies, ensuring they have the necessary laboratory space and expertise to thrive. Andrew MacIsaac, CEO of API, commented on the significance of Nanostics’ relocation, stating, “The BBDC is designed for exactly this—giving life sciences companies the lab space and support they need to grow, stay competitive, and impact patients here and around the world.”

The collaboration between Nanostics and API will not only benefit the company but is also expected to play a vital role in the wider Canadian healthcare landscape. With a commitment to improving patient outcomes, the lab's advanced capabilities are set to benefit men across Canada, providing them with critical diagnostic tools essential for managing their health amidst the challenges of prostate cancer.

In summary, the new accreditation from CPSA represents a pivotal advancement for Nanostics. As it embarks on this new journey at the BBDC, the company is poised to make a lasting impact on prostate cancer diagnostics and treatments, potentially enhancing the lives of men battling this common yet formidable disease. With innovation at its core, Nanostics is undoubtedly a company to watch in the realms of health technology and patient care.